BioSpace News Archive

Deals

Canon Medical System Corporation partners with ACT Genomics for Precision Cancer Medicine Service in Japan

Canon Medical System Corporation completed the acquisition of the majority shares of ACTmed

September 21, 2018
·
2 min read
Drug Development

Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with Previously Treated Non-Small Cell Lung Cancer at Annual Meeting of the Chinese Society of Clinical Oncology

Innovent Biologics, Inc. today presented clinical research data on cohort C at the 2018 Annual Meeting of Chinese Society of Clinical Oncology (CSCO).

September 21, 2018
·
5 min read
Business

uBiome Announces Expansion into Microbiome-Based Therapeutics, Appoints Pharmaceutical Veteran Joseph Jimenez to Board of Directors

uBiome Opens Therapeutics Headquarters in Cambridge, Massachusetts to Support Drug Discovery and Development

September 21, 2018
·
4 min read
Deals

BioTime Warrants to Expire on October 1, 2018

BioTime, Inc. is advising the holders of its publicly traded warrants (NYSE American: BTX.WS) that the warrants will expire and not be exercisable after 5:00 p.m., New York City time, on October 1, 2018 (the “Expiration Date”).

September 21, 2018
·
3 min read
Policy

AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia

If approved by the European Commission (EC), VENCLYXTO® plus rituximab would be the first chemotherapy-free combination regimen with a fixed duration of treatment for patients with chronic lymphocytic leukemia who have received at least one prior therapy.

September 21, 2018
·
11 min read
Lilly Receives Positive CHMP Opinion for Emgality™ (galcanezumab) for the Prophylaxis of Migraine in Adults

Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality™ (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month.

September 21, 2018
·
6 min read
Business

Hesperos, Inc. Among GrowFL 2018 Florida Companies to Watch

Hesperos, Inc. has announced that it has been named one of the 50 statewide companies expected to see significant growth over the next several years by GrowFL.

September 21, 2018
·
4 min read